Targeted Oncology2h
Timing of MRD Testing in Lung Cancer Affects Patient Outcomes
Oleg Gligich, MD, assistant professor at the Columbia University Division of Hematology/Oncology at Mount Sinai Medical ...
Targeted Oncology7h
Emerging Data on Oral SERDS
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating novel uses of oral selective ...
Targeted Oncology11h
Access to Primary Care and Its Impact on Endometrial Cancer Diagnosis
Alexander J. Fife, MD, discussed the challenges of diagnosing endometrial cancer, highlighting delays in care.
Targeted Oncology8h
EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study ...
Targeted Oncology8h
Elacestrant as second-line therapy for ESR1m, endocrine-sensitive disease
Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 ...
Targeted Oncology10h
FDA Approves First Oral Liquid Imatinib for Leukemia and Other Cancers
Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.
Targeted Oncology12h
Efficacy in Platinum-Sensitive vs Platinum-Resistant SCLC
Joshua K. Sabari, MD, discusses the antitumor activity of second-line lurbinectedin, noting an ORR of 45%, a median DOR of ...
Targeted Oncology12h
Comparative Efficacy and Future Directions in SCLC Treatment
Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them ...
Targeted Oncology8h
Co-occurrence of ESR1m with other alterations
Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations (ESR1m) frequently co-occur with other genetic alterations such as PIK3CA, TP53, and HER2-low expression, and ...